Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 5,126 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HIV - Human Immunodeficiency Virus Clear all
Completed Phase 2 Interventional

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

NCT00298350
View directory record Official record
Conditions
HIV, HIV-1, Human Immunodeficiency Virus
Interventions
GS-9137 - A Novel HIV-1 Integrase Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

NCT02357368
View directory record Official record
Conditions
HIV, Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD), ParaGard® T 380A Intrauterine Copper Contraceptive
Drug · Device
Lead sponsor
Lisa Haddad
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Milk Thistle on the Pharmacokinetics of Indinavir

NCT00011635
View directory record Official record
Conditions
HIV Infection, Healthy
Interventions
Silymarin (milk thistle)
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 2:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities

NCT06428643
View directory record Official record
Conditions
Chlamydia, Gonorrhea, Hiv, Syphilis
Interventions
Chlamydia, gonorrhea, syphilis, and HIV screening
Other
Lead sponsor
Tulane University
Other
Eligibility
15 Years to 26 Years
Enrollment
2,322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Completed No phase listed Observational

HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers

NCT00491335
View directory record Official record
Conditions
HIV Infections, AIDS, Lung Cancer, Tobacco Addiction, Drug Addiction
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

NCT03409276
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 8, 2026, 2:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History Study of HIV Acquired in Infancy or Childhood

NCT00924365
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

NCT00000899
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Lamivudine, Filgrastim, Stavudine, Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 8, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts

NCT03038828
View directory record Official record
Conditions
Perianal Warts
Interventions
Leukocyte Interleukin, Injection
Biological
Lead sponsor
CEL-SCI Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NCT00100698
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
recombinant human growth hormone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000887
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Nelfinavir mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
7
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brief Intervention for Rural Women at High Risk for HIV/HCV

NCT01840722
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome Virus, Hepatitis C, Drug Abuse
Interventions
MI-based HIV Risk Reduction
Other
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Transitions: Linkages From Jail To Community

NCT00841711
View directory record Official record
Conditions
HIV, Substance Abuse, HIV Infections
Interventions
Intensive Case Management
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New Haven, Connecticut • Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 8, 2026, 2:17 AM EDT
Completed No phase listed Observational Results available

SHARE Project Define

NCT06125509
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 29 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

NCT00000772
View directory record Official record
Conditions
HIV Infections
Interventions
Ribavirin, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1

NCT06004830
View directory record Official record
Conditions
Alcohol Use Disorder, Hiv
Interventions
Spironolactone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Recruiting Phase 2 Interventional

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Doravirine, 2 NRTIs, DOR/3TC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
4 Weeks to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Recruiting Not applicable Interventional

Comprehensive HIV and Harm Prevention Via Telehealth

NCT05897099
View directory record Official record
Conditions
HIV Infections
Interventions
Comprehensive Tele-harm Reduction, Off-site Linkage to HIV Prevention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Program Refinements to Optimize Model Impact and Scalability Based on Evidence

NCT03628287
View directory record Official record
Conditions
Hiv
Interventions
Revised Care Coordination Program, Original Care Coordination Program
Other
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
17
States / cities
Brooklyn, New York • Elmhurst, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting

NCT07498153
View directory record Official record
Conditions
Syphilis, HIV Infections
Interventions
Chembio HIV/Syphilis rapid POC test
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 65 Years · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Social Media Support and Financial Incentives on PrEP Adherence

NCT03078153
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
Financial Incentive, Social Media Group
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 24 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR

NCT01889719
View directory record Official record
Conditions
HIV
Interventions
MVA-CMDR
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 62 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 8, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

NCT02707900
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vorinostat, AGS-004
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 8, 2026, 2:17 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves

NCT03278990
View directory record Official record
Conditions
HIV Prevention
Interventions
Value Affirmation and Future Selves Combination, Control writing exercise
Behavioral
Lead sponsor
Stuart Fisk
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 8, 2026, 2:17 AM EDT